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Malignant gliomas are characterized by accumulated aberrations affecting TP53, PTEN, andRB1 signaling. In
this issue, Chow et al. discover that combinatorial loss of these tumor suppressors in mice induces gliomas
with unexpected degrees of similarity to human pathologic, genomic, and expression subclasses recently
revealed by large-scale genomic studies.Malignant gliomas represent one of the
most studied and well-characterized
human cancers at the genetic and expres-
sion-profiling level. The most common of
these tumors, glioblastoma (GBM), has
been the focus of several large scale inte-
grated genomic efforts and was in fact the
first cancer genome characterized by the
Cancer Genome Atlas project (Cancer
Genome Atlas Research Network, 2008).
One of the consensus findings of these
studies has been the centrality of alter-
ations in the TP53, PI3K/PTEN, and RB1
signaling pathways in human gliomas.
While these efforts have yielded an excel-
lent snapshot of GBM at a single point in
time, they have generated only indirect
hints at the combinatorial hierarchy of
genetic events needed for initiation and
progression, due to the inaccessibility
and limited availability of early stage
neoplastic tissue.
Genetically engineered mouse models
(GEMMs) of gliomas are a useful tool in
the evaluation of tumor initiation, progres-
sion, and origins of gliomas, as the
timing and location of mutations may be
precisely controlled. Glioma modelers
have been fortunate in that many aspects
of glioma biology are faithfully reproduced
upon introduction of relatively few muta-
tions into the mouse genome. In some
instances, mouse model phenotypes
have even presaged the future impor-
tance of particular genetic alterations,
such as inactivating mutations of TP53
and NF1, once thought to represent only
infrequent events in adult GBM (Reilly
et al., 2000; Zheng et al., 2008). Withrespect to tumor origins, mouse studies
using noninducible cre-recombinase sys-
tems have established that mouse
gliomas readily arise from proliferative
Gfap and Nestin positive stem/progenitor
cells within the subventricular zone
(SVZ), but have generated less clear evi-
dence for origins from mature astrocytes,
for which astrocytomas were originally
named. Despite these contributions to
the field, there remains significant debate
about whether simplified mouse models
can sufficiently substitute for primary
tissue or glioma cell lines in recreating
the genomic and expression heteroge-
neity of the original disease, particularly
at the level that would make them useful
for preclinical studies and evaluation of
targeted therapeutics.
In this issue of Cancer Cell, Chow et al.
(2011) show that mouse models can still
hold their own in this debate. The authors
initially sought to carefully dissect the
combinatorial interactions of the critical
GBM tumor suppressor genes p53,
Pten, and Rb1 in the adult brain. Prior
work indicated roles for each of these
genes in the growth regulation of neural
stem/progenitor cells. Combined loss of
p53 and Pten has been shown to be
sufficient for transforming neural stem
cells of the SVZ into malignant gliomas
using conditional knockout mice (Jac-
ques et al., 2010; Zheng et al., 2008).
However, the techniques employed in
these analyses left open questions about
the role of these genes in non-stem cells
of the adult brain. To address these issues
from a different perspective, Chow et al.Cancer Cell 1(2011) used an inducible GFAP-CreER
mouse driver to achieve combinatorial
deletion of all three tumor suppressors
(p53loxP/loxP, PtenloxP/loxP, and Rb1loxP/loxP)
in up to 50% of the mature astrocytes
in the adult brain and only a small percent-
age of stem/progenitor cells within the
SVZ (Figure 1A).
As expected, individual loss of tumor
suppressor genes was generally insuffi-
cient for glioma formation, although the
loss of p53 alone did cause a low inci-
dence of glioma formation, in concor-
dance with previous reports. However,
combined loss of p53 with either Pten
and/or Rb1 in the adult brain led to
a high incidence of malignant gliomas
with different latencies and histopathol-
ogies. One novel result was the finding
that layering of Rb1 loss on top of
p53/Pten loss did not produce very signif-
icant changes at either the clinico-patho-
logic level or in the incidence of tumor
formation (87% incidence with p53:Pten
loss versus 85% in p53:Pten:Rb1 loss).
However, Rb1 loss produced decreased
latency of tumor formation (211 days
for p53:Pten versus 159 days for
p53:Pten:Rb1) as well as marked differ-
ences in secondary genomic aberrations
in the tumors (see below).
The current study by Chow et al. (2011)
identifies nearly all of the tumors as
anaplastic astrocytomas (WHO grade III)
and less frequently glioblastomas with
necrosis (WHO grade IV). Of particular
value is the finding that the gliomas
appeared to develop in the absence of
any detectable low-grade precursor—a9, March 15, 2011 ª2011 Elsevier Inc. 295
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Pten Increased stem proliferation, migration defect, neuronal hypertrophy 0% - - - 
Rb1 Increased brain size 0% - - - 
p53 Anaplastic astrocytoma (Gr III) Rare (~17%) - - - 
Pten:Rb1 No brain tumor, few pituritary tumors 0% - - - 
p53:Rb1 Astrocytoma (Gr III, IV); central PNET, olfactory PNET, (Gr IV) 37% Long (~350) - - 
p53:Pten Anaplastic astrocytoma (Gr III), myxoid glioma , GBM (Gr IV) 87% Medium (211) Pdgfra, Met, Egfr Proneural = proliferative = mesenchymal 
p53:Pten:Rb1 Anaplastic astrocytoma (Gr III), myxoid glioma, GBM (Gr IV) 85% Short (159) Pdgfra Proneural = proliferative > mesenchymal 
Figure 1. Combinatorial Tumor Suppressor Loss in Mouse Glioma Models Reveals Novel Correlations to Human Glioma Drivers and
Expression Subclasses
(A) Schematic describing conditional and inducible deletion of p53, Pten, andRb1 in Gfap-positive adult brain astrocytes and stem cells and subsequent compar-
ative genomic correlations with human GBM datasets.
(B) Summary of specific combinations of suppressor deletion reveal hidden secondary genetic and subclass differences in adult murine high-grade gliomas.
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model of de novo human primary GBM.
The authors make note of interesting
phenotypic diversity in the tumors, with
some similarities to human tumors such
as myxoid phenotype and some features
of central primitive neuroectodermal
tumors (cPNET). Such diversity was also
noted in a prior study using noninducible
p53:Pten deletion, but this model showed
multifocal mixed oligodendroglial and as-
trocytic tumors in the same brain (Zheng
et al., 2008). Future studies may be
needed to determine whether the differ-
ence in these phenotypes are a result of
timing of deletion or of the cell compart-
ments in which tumor suppressor loss
occurs. Collectively, it seems that one
can conclude that alterations in the p53
pathway are key initiating events in
murine and human high-grade glioma
formation and also suggest that the role
of Pten and Rb1 may be more crucial for
tumor progression.
Chow et al. (2011) were particularly
interested in determining whether gliomas
might originate from mature astrocytes,
and in fact uncovered evidence to support
this hypothesis. While a subset of gliomas296 Cancer Cell 19, March 15, 2011 ª2011 Ein theGFAP-CreER:p53:Pten background
arose in contact with the SVZ region, 22%
of tumors developed at distant sites
including the cerebellum, brainstem, and
spinal cord without connection to the
SVZ or other known germinal zones in
the adult brain. The authors make the
cogent argument that these tumors most
likely arise from genomic deletion in
mature astrocytes; however, even with
the advanced techniques used, it remains
a challenge to conclusively track the
precise origin of the tumors. Certainly
these studies do not address the potential
contribution of ‘‘distributed’’ progeni-
tors—such as NG2/Olig2+ cells or oligo-
dendroglial progenitors—to tumor forma-
tion, despite evidence that such cells
may be the most closely related to
gliomas. Future studies precisely target-
ing oligodendroglial and other cellular
compartments will likely be helpful in
glioma models, given the utility of this
approach in dissecting the origins of other
brain tumors such as medulloblastoma
(Gibson et al., 2010; Schuller et al., 2008).
Clearly, themost unexpected turn in the
work came when the authors delved into
the hidden genomic and RNA expressionlsevier Inc.patterns in the murine tumors. Using
array comparative genomic hybridization
(aCGH), the authors discovered focal as
well as large-scale genomic aberrations
characteristic of human GBM genomic
subclasses. For example, p53:Pten
tumors had acquired secondary amplifi-
cations of receptor tyrosine kinases
(RTKs), including Pdgfra, Egfr, and Met,
which are hallmark events in human
GBM pathogenesis (Figure 1B). Interest-
ingly, p53:Pten:Rb1 tumors seemed to
acquire only Pdgfra amplification and
had a distinctly different genomic profile
compared with p53:Pten tumors, sug-
gesting that the loss of Rb1 removed the
selective pressure for development of
additional RTK activation. These
findings are reminiscent of comparative
oncogenomic studies in T-ALL and other
cancers, which leads one to conclude
that secondary induction of copy number
alterations in mouse models may not be
a rare event (Maser et al., 2007). Such
findings provide immediate opportunities
to investigate the basic mechanisms by
which tumor suppressor losses might
induce secondary genomic alterations in
glioma progression and should help
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for functional studies.
As a final step, the authors sought
to determine to what degree murine
gliomas might recapitulate gene expres-
sion subclasses of human glioblastoma
described in prior studies (Phillips
et al., 2006; Verhaak et al., 2010). Unsu-
pervised hierarchical clustering analysis
across p53:Pten and p53:Pten:Rb1
tumors generated three clusters of murine
gliomas, HC1, HC2, and HC3, with signif-
icant similarity to proneural and mesen-
chymal subclasses of GBM. One inter-
esting deviation from the human data,
however, was that correlation of the
mouse histology and genetics with the
murine expression subclasses was weak,
yet such correlations are clearly present in
human GBM, particularly for the mesen-
chymal subclass that is associated with
NF1 loss, necrosis, and inflammation.
While further refinement of mouse-to-
human expression correlations is likelyrequired, the results support the idea
that mouse glioma models could be very
helpful in exploring the diversity of human
GBM subclasses with implications for
better diagnosis and prediction of prog-
nosis in patients. What seems equally
clear is that mouse models can still
generate novel ways to surprise and
inform investigators who seek to under-
stand these most challenging cancers of
the brain.REFERENCES
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Reactive oxygen species (ROS) mediate various cell fate decisions in normal and transformed cells. In this
issue of Cancer Cell, Zhu et al. demonstrate the ability of ANGPTL4 to engage integrin-dependent survival
signals by activation of the NADPH oxidase Nox1, thus mimicking anchorage conditions and bypassing
anoikis by controlling ROS.Cancer cells have long been known to
display abnormal redox metabolism,
releasing increased levels of reactive
oxidants compared with normal cells.
The exact significance of such reactive
oxygen species (ROS) production as it
pertains to malignant transformation,
however, has been less clear. ROS cause
oxidative stress, which results in muta-
tions to both nuclear and mitochondrial
DNA. With loss of fail-safe death andsenescence mechanisms, such genomic
damage has been proposed to accelerate
transformation and cancer progression.
Besides creating a stress response,
however, ROS clearly participate in phys-
iologic signaling at a variety of levels,
requiring tight spatial and temporal regu-
lation of oxidants by normal cells (Terada,
2006). In this capacity, ROS control prolif-
eration, differentiation, junction formation,
and response to cytokines and othersoluble factors. Given their propensity to
produce increased levels of ROS, are
cancer cells able to appropriate these
oxidant-dependent signals as a means
of dysregulating proliferative and survival
pathways? In this issue of Cancer Cell,
Zhu et al. (2011) uncover a role for angio-
poietin-like 4 (ANGPTL4) in activating
integrin-related, oxidant-dependent sur-
vival pathways, despite the loss of matrix
attachment. This highjacking of normal9, March 15, 2011 ª2011 Elsevier Inc. 297
